Showing 1 – 20 of 244
Relevance | Newest | Oldest |
  • JAMA July 25, 2017

    Figure 1: Screened, Excluded, and Included Patients in the Study of Targeted Temperature Management

    OHCA indicates out-of-hospital cardiac arrest; ICU, intensive care unit; ROSC, return of spontaneous circulation.aReasons for not meeting inclusion (eligibility) criteria were as follows: not cardiac OHCA (n=75), age (n=53), Glasgow Coma Scale score >8 (n=49), and no stable ROSC (n=14).bExclusion criteria met were as follows: estimated time from collapse to ROSC >60 min (n=40), cardiac arrest with presumed noncardiac cause (eg, trauma, aorta dissection, intracerebral disease, massive bleeding, hanging, or hypoxemia) (n=63), in-hospital cardiac arrest (n=6), terminal disease or do-not-resuscitate order (n=15), severe coagulopathy (anticoagulant therapy, including thrombolysis, was not an exclusion criteria) (n=8), unwitnessed OHCA with asystole as first rhythm (n=21), time from cardiac arrest to initiation of cooling >240 min (n=19), neurologic disease with cognitive impairment (n=8), persistent cardiogenic shock, systolic blood pressure <80 mm Hg despite vasoactive treatment, or aortic balloon pump intervention (n=46), suspected or confirmed acute intracerebral bleeding (n=9), suspected or confirmed acute stroke (n=6), and acute coronary artery bypass surgery (n=1).cOther reasons for exclusion were as follows: patient died before enrollment (n=10), other interventional study precluding co-enrollment (n=5), patients transferred to other ICU because of bed availability (n=5), and patient not native to country of treatment, rendering follow-up difficult or impossible (n=3).dThe patient lost to follow-up was known to be alive and was included in the survival analyses, but could not be included in the primary analyses due to lack of primary outcome data.
  • Mixing Study for Evaluation of Abnormal Coagulation Testing

    Abstract Full Text
    JAMA. 2016; 316(20):2146-2147. doi: 10.1001/jama.2016.15749

    An 84-year-old woman with a history of chronic kidney disease, prior stroke, and hypertension but no personal or family history of bleeding disorders was admitted with a 2-week history of spontaneous subcutaneous ecchymoses and hematomas. She had normal vital signs, laboratory results showing isolated severe anemia but unremarkable for other causes of anemia, and a large soft-tissue hematoma in the left chest wall without evidence of internal hemorrhage. How do you interpret these test results?

  • Cutaneous Necrosis of the Ears

    Abstract Full Text
    JAMA. 2016; 316(4):450-451. doi: 10.1001/jama.2016.7847

    A 22-year-old woman presented with a 2-month history of fevers and pleuritic chest pain and a 2-day history of cutaneous necroses on her ears, without trauma. Evaluation revealed abnormal coagulation values and a deep vein thrombosis in one leg. What would you do next?

  • JAMA February 23, 2016

    Figure 4: Serum Lactate Level Analysis

    Adjusted odds ratio for actual serum lactate levels for the entire septic shock cohort (N = 18 840). The covariates used in the regression model include region (United States and Europe), location where sepsis was suspected (emergency department, ward, or critical care unit), antibiotic administration, steroid use, organ failures (pulmonary, renal, hepatic, and acutely altered mental state), infection source (pneumonia, urinary tract infection, abdominal, meningitis, and other), hyperthermia (>38.3°C), hypothermia (<36°C), chills with rigor, tachypnea (>20/min), leukopenia (<4000 cells/µL), hyperglycemia (plasma glucose >120 mg/dL [6.7 mmol/L]), platelet count <100 ×103/μL, and coagulopathy (eMethods 3 in the Supplement). The adjusted odds ratio (OR) for the 6 groups presented in eTable 7 in the Supplement and the adjusted OR for the individual variables (lactate, vasopressor therapy, and fluids) are reported in eTable 8 in the Supplement. To convert serum lactate values to mg/dL, divide by 0.111.
  • New Option for Bleeding Disorder

    Abstract Full Text
    JAMA. 2016; 315(3):243-243. doi: 10.1001/jama.2015.18731
  • Bleeding Disorders

    Abstract Full Text
    free access
    JAMA. 2012; 308(14):1492-1492. doi: 10.1001/jama.2012.4089
  • JAMA May 9, 2007

    Figure: Cardiologists Get Wake-up Call on Stents

    Medical therapy, including drugs for hypertension, dyslipidemia, and clotting, along with lifestyle modification programs, should be the first treatment options for patients with stable coronary artery disease.
  • Blood Safety Monitoring Among Persons With Bleeding Disorders—United States, May 1998–June 2002

    Abstract Full Text
    JAMA. 2003; 289(5):541-543. doi: 10.1001/jama.289.5.541
  • JAMA May 1, 2002

    Figure 3: Lesion of Cutaneous Anthrax Associated With Microangiopathic Hemolytic Anemia and Coagulopathy in a 7-Month-Old Infant

    By hospital day 12, a 2-cm black eschar was present in the center of the cutaneous lesion. Reprinted from Freedman et al.
  • Cutaneous Anthrax Associated With Microangiopathic Hemolytic Anemia and Coagulopathy in a 7-Month-Old Infant

    Abstract Full Text
    free access
    JAMA. 2002; 287(7):869-874. doi: 10.1001/jama.287.7.869
  • Better Control Coming for Clotting and Bleeding

    Abstract Full Text
    JAMA. 1999; 282(16):1509-1510. doi: 10.1001/jama.282.16.1509-JMN1027-3-1
  • The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report

    Abstract Full Text
    JAMA. 2003; 289(19):2560-2571. doi: 10.1001/jama.289.19.2560
  • Coagulation: A History of Blood Coagulation

    Abstract Full Text
    JAMA. 2002; 287(8):1051-1052. doi: 10.1001/jama.287.8.1051-JBK0227-3-1
  • Human Blood Coagulation and Its Disorders

    Abstract Full Text
    JAMA. 1958; 167(4):524-524. doi: 10.1001/jama.1958.02990210110022
  • Human Blood Coagulation and Its Disorders

    Abstract Full Text
    JAMA. 1953; 153(12):1140-1140. doi: 10.1001/jama.1953.02940290072059
  • Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2017; 317(7):738-747. doi: 10.1001/jama.2016.21037

    This randomized trial compares the effects of fibrinogen concentrate vs placebo on intraoperative blood loss in patients at high-risk of bleeding undergoing elective cardiac surgery.

  • Tests of Blood Coagulation and Hemostasis: III. The Partial Thromboplastin Time

    Abstract Full Text
    JAMA. 1967; 199(3):201-201. doi: 10.1001/jama.1967.03120030105019
  • Treatment of Haemophilia and Other Coagulation Disorders

    Abstract Full Text
    JAMA. 1966; 198(5):565-566. doi: 10.1001/jama.1966.03110180109044
  • Activated Coagulation Time of Whole Blood

    Abstract Full Text
    JAMA. 1966; 196(5):436-440. doi: 10.1001/jama.1966.03100180108036
  • Blood Disorders in the Elderly

    Abstract Full Text
    JAMA. 2008; 300(18):2184-2185. doi: 10.1001/jama.2008.618